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In March, after years of intense pressure from the US and other countries, Argentina and Brazil
took decisive steps to enact legislation that would bring their intellectual property rights and
commercial research laws into line with World Trade Organization (WTO) guidelines. The measures
have especially strong implications for foreign drug manufacturers, who have battled with the
Argentine and Brazilian governments over property rights for products developed by them. Of the
two countries, Brazil appears to have taken the strongest step to protect the rights of US and other
foreign pharmaceutical companies. On March 4, the Brazilian Senate gave final approval to the
country's first-ever comprehensive protection for intellectual property rights. However, the measure
still awaits approval from the lower house, and then it must be signed by President Fernando
Henrique Cardoso.
While Brazil's intellectual property protection measure has not yet become the law of the land,
Argentina took the final steps to finalize its own patent protection laws. On March 20, President
Carlos Menem signed a decree that formalizes legislation to protect intellectual property and other
commercial research. The bill signed by Menem, which falls short of that demanded by the US
and some European governments, is still considered significant, since it ends an extended dispute
between the executive and the legislative branches regarding this issue. For almost a year, Menem
and the legislature had been entangled in a series of disagreements on how much protection to offer
foreign companies while still protecting the interests of Argentina, especially the drug industry.
In March 1995, the Argentine Congress had passed a patent rights law that fundamentally altered
the country's outdated intellectual property rights legislation by extending patent protection to
pharmaceuticals. Drug products had not been included in the previous Argentine patent law, in
effect since 1864. The original bill was partially vetoed by Menem in April after strong pressure from
the US and other countries, which said the legislation provided inadequate patent protections (see
NotiSur, 04/27/95). However, the Argentine Senate then overrode Menem's partial veto in June of
last year (see NotiSur, 06/08/95).
fter negotiations with members of the governing Partido Justicialista (PJ), Menem and the legislature
drafted a compromise measure in September that appeared to be acceptable to both sides (see
NotiSur, 10/12/95). The compromise measure, however, was still unacceptable to the US and
some European countries, which claimed that the legislation violated clauses approved during the
Uruguay Round negotiations of the General Agreement on Tariffs and Trade (GATT). Responding
to those concerns and hoping to avoid retaliation, Menem unilaterally altered language in the
compromise bill to make it more palatable to the US and European countries.
By taking this action, Menem immediately drew protests from Argentine legislators and was forced
to enter into a series of new negotiations (see NotiSur, 11/30/95). These negotiations resulted in a
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final agreement in February of this year. This final compromise offers Argentine companies the
same five-year transition period negotiated in the previous compromise bill last September. This
means that multinational drug companies will not be able to claim patent rights to their products
in Argentina until at least the year 2001. Argentina's claim to the right for a transition period for its
pharmaceutical industry is based on a definition developed during the Uruguay Round negotiations
of the GATT. In the negotiations, GATT member countries agreed to allow some nations that qualify
for "least developed country" (LDC) status to delay adoption of GATT patent laws for a period for 10
years.
Argentina initially claimed to qualify for the LDC designation and the 10-year transition period.
However, US and European countries disputed this claim, since Argentina's drug industry is
the thirteenth largest in the world. The US and European countries charged that Argentina
was obligated to immediately enforce GATT laws and offer royalties to US pharmaceutical
manufacturers. If not, they threatened trade retaliation against Argentina. Because of this threat
of retaliation, the Menem administration and the Argentine legislature sought the compromises
that eventually led to the five-year transition period. During a trip to Washington, a delegation of
five Argentine legislators met with US officials to explain that the measure complies with norms
established by the GATT. Argentine deputy Humberto Roggerio told reporters that he hoped the US
"would cease its pressure" now that President Menem has signed a patent protection bill into law.
For his part, Foreign Minister Guido Di Tella reinforced the message during a session with US Trade
Representative Mickey Kantor at a meeting of hemisferic trade ministers in Cartagena, Colombia, in
mid-March (see NotiSur, 03/28/96). As of early April, the US had still not issued an official response
to the new Argentine patent law, although during a recent trip to Argentina in late February, US
Secretary of State Warren Christopher raised objections about the compromise measure during
meetings with Foreign Minister de Tella and Economy Minister Domingo Cavallo. At that point,
it appeared very likely that Menem would sign the legislation. In contrast to the initially lowkey response from the US government, multinational pharmaceutical companies immediately
denounced the bill.
Speaking to reporters immediately after Menem signed the bill, Felix Rozanski who represents
foreign drug manufacturers in Argentina said the measure was "unsatisfactory." He explained
that the five-year transition period in the new Argentine law contrasts with the one-year transition
allowed in the recent bill passed by the Brazilian Senate. To support his position, Rozanski repeated
claims by US drug companies that they are losing US$540 million per year in potential royalties in
Argentina for medicines they have developed. The companies continue to demand that Argentina
fully comply with GATT rules. Still, the limited patent protection in the Argentine decree has not
significantly deterred investment by multinational companies in the Argentine pharmaceutical
industry, as some members of the industry had feared.
On March 11, US-based Bristol Myers Squibb Co. announced the purchase of Argentina's
Argentia, a privately held manufacturer of antibiotic, respiratory, and gastrointestinal products.
"The acquisition of Argentia propels Bristol-Myers Squibb into a leadership position as one of
Argentina's largest pharmaceutical companies and positions our company for future growth in one
of the most promising markets in Latin America," said Bristol-Myers Squibb chief executive officer
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Charles Heimbold issued shortly after the purchase. Meanwhile, in contrast to the muted reaction
to the measure approved by Argentina, the US government praised the Brazilian Senate's vote to
approve patent protection legislation. Speaking to reporters during his Latin American trip, US
Secretary of State Christopher said that the Brazilian Senate vote reaffirms Brazil's commitment
to the decisions reached at the Summit of the Americas in Miami in December 1994. "Now, Brazil
should join us in energizing the effort to achieve a free trade area of the Americas by 2005,"
Christopher said during a stop in Manaus, Brazil.
Indeed, the Senate approval to extend full protection to pharmaceutical and other similar research
represented a major step in cementing relations between the US and Brazil, since it removes a
source of tension between the two countries that has existed since at least 1986. According to trade
analysts, the measure passed by the Brazilian Senate goes beyond any legislation approved in
the past, since the bill extends full protection to all pharmaceutical and other scientific research.
Previous legislation passed in Brazil only extended intellectual property protection to finished
products, and not to the research itself. However, the measure must still gain approval from the
lower house, which had already approved a more limited patent protection bill.
Members of President Fernando Henrique Cardoso's governing party, who helped draft the bill,
said the executive was confident the lower house would approve the measure. But as of early April,
the Chamber of Deputies had not voted on the bill. The Brazilian Senate legislation, however, met
with significant opposition from the country's pharmaceutical manufacturers. The manufacturers,
represented by the pharmaceutical industry chamber Farmaetica, took out a large advertisement
in newspapers in Brasilia during early March in an attempt to influence the vote in the Senate. In
expressing its opposition to the measure, Farmaetica emphasized that the group was not opposed to
protection of intellectual property and enforcement of patent laws.
However, the group argued that this particular bill was unwise since the measure would give US
companies an unfair advantage not only in marketing of pharmaceuticals, but also in processed
foods, agrochemicals, and biotechnology products in Brazil. Farmaetica argued that giving US and
other foreign companies an advantage in Brazil would force many Brazilian drug manufacturers
out of business, which would result in the direct loss of jobs. "The measure is an artificial rule
imposed by US companies, which would like to increase their royalties," said the group. However,
the pharmaceutical industry was not unanimous in its opposition to the bill. Interfarma, the
organization representing pharmaceutical researchers, fully endorsed the bill, since the legislation
would encourage foreign pharmaceutical companies to invest in Brazil. Interfarma representatives
dismissed the concerns by pharmaceutical manufacturers about possible job losses.
"To the contrary, the approval of the law will stimulate new investments in research and also
promote technology transfer, which will surely create new jobs in areas that Brazil considers
strategic and fundamental," Interfarma said. According to the New York Times, the patent
legislation removes the final obstacle for US investment in Brazil and, once enacted, could attract
millions of dollars to the Brazilian pharmaceutical market, which is the world's fifth largest.
(Sources: Journal of Commerce, 04/28/95, 09/18/95; Inter Press Service, 02/29/96; Agence FrancePresse, 02/28/96, 03/01/96, 03/20/96; New York Times, 03/04/96; PRNewswire, 03/11/96; Argentine
news service DYN, 03/22/96; Periodico Los Andes (Argentina), 03/23/96)
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